PhaseBio Pharmaceuticals Competitors and Similar CompaniesClear all
PhaseBio Pharmaceuticals's competitors and similar companies include Cosmo Pharmaceuticals, Sangamo Therapeutics, PanOptica, Amicus Therapeutics and Altimmune.
 PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals is a biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. |  Cosmo Pharmaceuticals Cosmo Pharmaceuticals is a company that focuses on solutions in the areas of astroenterology and endoscopy. |  Sangamo Therapeutics Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies. |  PanOptica PanOptica is a biopharma company developing ophthalmic therapeutics for the treatment of eye diseases. |  Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. | ||
Founding Date | Founding Date 2002 | Founding Date 1997 | Founding Date 1995 | Founding Date 2009 | Founding Date 2002 | Founding Date 1997 |
Type | Type Public | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | ||||||
Locations | Locations Malvern, US HQ | Locations Dublin, IE HQ | Locations Brisbane, US HQ Nice Area, FR Cheltenham, GB London, GB Richmond, US | Locations Mount Arlington, US HQ | Locations Philadelphia, US HQ Northbridge, AU Pointe Claire, CA Paris, FR München, DE Dublin, IE Milano, IT see more | Locations Gaithersburg, US HQ |
Employees | Employees 22 | Employees 321 | Employees 35417% increase | Employees 5 | Employees 58415% increase | Employees 691% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 416.4 m | Valuation ($) N/A | Valuation ($) 3.4 b | Valuation ($) 498.2 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $10.8m (FY, 2021) | Revenue (est.) €104.2m (FY, 2025) | Revenue (est.) $39.6m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $634.2m (FY, 2025) | Revenue (est.) $41k (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods €40.4m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $72.9m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €70.9m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $561.3m (FY, 2025) | Gross profit N/A |
Net income | Net income ($131.1m) (FY, 2021) | Net income (€3.5m) (FY, 2025) | Net income ($122.9m) (FY, 2025) | Net income N/A | Net income ($27.1m) (FY, 2025) | Net income ($88.1m) (FY, 2025) |
Funding | ||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 74.2m | Total funding raised $ 57.3m | Total funding raised $ 88m | Total funding raised $ 47.7m |
For sources of this data, please see the company profile
View Company Profiles
Cosmo Pharmaceuticals
HQ
Dublin, IE
Employees
321
Cosmo Pharmaceuticals is a company that focuses on solutions in the areas of astroenterology and endoscopy.
View companySangamo Therapeutics
HQ
Brisbane, US
Employees
354↑ 17% increase
Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies.
View companyPanOptica
HQ
Mount Arlington, US
Employees
5
PanOptica is a biopharma company developing ophthalmic therapeutics for the treatment of eye diseases.
View companyAmicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
View company